Published in Int J Cancer on August 15, 1975
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity (2007) 5.50
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties. Br J Cancer (1978) 3.38
Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice. I. Characterization of natural killer cell induction. J Exp Med (1978) 3.31
p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med (1997) 2.70
NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol (2013) 2.39
First do no harm: uterine natural killer (NK) cells in assisted reproduction. Hum Reprod (2015) 2.14
NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol (2009) 2.12
Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems. J Exp Med (1976) 2.11
Identification of a cell-surface antigen selectively expressed on the natural killer cell. J Exp Med (1977) 1.97
Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice. J Exp Med (1979) 1.81
Latent herpesvirus infection arms NK cells. Blood (2010) 1.80
Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev (2008) 1.74
Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med (1982) 1.73
Target-effector interaction in the natural killer cell system: isolation of target structures. Proc Natl Acad Sci U S A (1979) 1.71
The role of natural killer cells and antibody-dependent cell-mediated cytotoxicity during murine cytomegalovirus infection. J Exp Med (1979) 1.51
Natural health products, modulation of immune function and prevention of chronic diseases. Evid Based Complement Alternat Med (2005) 1.51
Accumulation of natural killer and cytotoxic T large granular lymphocytes in the liver during virus infection. J Exp Med (1986) 1.43
Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol (2008) 1.42
Correlation of natural killer cell activity and clearance of Cryptococcus neoformans from mice after adoptive transfer of splenic nylon wool-nonadherent cells. Infect Immun (1986) 1.41
Passive serum antibody causes temporary recovery from influenza virus infection of the nose, trachea and lung of nude mice. Immunology (1988) 1.40
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol (2013) 1.38
Receptor for transferrin may be a "target" structure for natural killer cells. Proc Natl Acad Sci U S A (1983) 1.37
Cytotoxic T lymphocyte hybridomas that mediate specific tumor-cell lysis in vitro. Proc Natl Acad Sci U S A (1981) 1.36
Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice. Proc Natl Acad Sci U S A (1981) 1.34
Role of natural killer cells in infection with the mouse pneumonitis agent (murine Chlamydia trachomatis). Infect Immun (1987) 1.33
Interleukin 2-induced proliferation of murine natural killer cells in vivo. J Exp Med (1990) 1.28
Uterine NK cells: active regulators at the maternal-fetal interface. J Clin Invest (2014) 1.23
Direct evidence that natural killer cells in nonimmune spleen cell populations prevent tumor growth in vivo. J Exp Med (1979) 1.22
Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol Immunother (2013) 1.22
Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease. Front Immunol (2013) 1.20
Natural cell-mediated cytotoxicity against Candida albicans induced by cyclophosphamide: nature of the in vitro cytotoxic effector. Infect Immun (1983) 1.20
Putting the natural killer cell in its place. Immunology (2006) 1.20
Generation of natural killer cells: an autonomous function of the bone marrow. J Exp Med (1977) 1.19
Spontaneous cell-mediated cytotoxicity in humans. Distribution and characterization of the effector cell. Clin Exp Immunol (1978) 1.15
The effect of passage in vitro and in vivo on the properties of murine fibrosarcomas I. Tumorigenicity and immunogenicity. Br J Cancer (1985) 1.15
The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood (2009) 1.15
Primate-specific regulation of natural killer cells. J Med Primatol (2010) 1.14
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov (2015) 1.14
Immunological memory within the innate immune system. EMBO J (2014) 1.14
Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy (2011) 1.11
In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats. J Exp Med (1990) 1.10
NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol (2014) 1.08
Expression and rearrangement of the alpha, beta, and gamma chain genes of the T cell receptor in cloned murine large granular lymphocyte lines. No correlation with the cytotoxic spectrum. J Exp Med (1986) 1.07
In vitro effects of natural killer cells against Paracoccidioides brasiliensis yeast phase. Infect Immun (1984) 1.07
Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol (2014) 1.07
Densely granulated murine NK cells eradicate large solid tumors. Cancer Res (2012) 1.04
Natural killer cells appear to play no role in the recovery of mice from Sindbis virus infection. Immunology (1981) 1.04
Natural killer cell responses to viral infection. J Innate Immun (2011) 1.03
Dendritic cell derived cytokines in human natural killer cell differentiation and activation. Front Immunol (2013) 1.03
The role of natural killer cells in sepsis. J Biomed Biotechnol (2011) 1.02
Selective blockade of human natural killer cells by a monoclonal antibody. Proc Natl Acad Sci U S A (1982) 1.01
Molecular cloning of gp42, a cell-surface molecule that is selectively induced on rat natural killer cells by interleukin 2: glycolipid membrane anchoring and capacity for transmembrane signaling. J Exp Med (1991) 1.00
The Critical Role of IL-15-PI3K-mTOR Pathway in Natural Killer Cell Effector Functions. Front Immunol (2014) 0.99
Studies of the function of natural killer-interferon system in patients with Sjögren syndrome. J Clin Invest (1982) 0.99
NK cells in therapy of cancer. Crit Rev Oncog (2014) 0.96
Mechanism of target cell recognition by natural killer cells: characterization of a novel triggering molecule restricted to CD3- large granular lymphocytes. J Exp Med (1991) 0.96
NK cells: immune cross-talk and therapeutic implications. Immunotherapy (2011) 0.96
A distinct subpopulation of human NK cells restricts B cell transformation by EBV. J Immunol (2013) 0.95
Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer. Gastric Cancer (2011) 0.94
Natural cytotoxicity of murine cytomegalovirus-infected cells mediated by mouse lymphoid cells: role of interferon in the endogenous natural cytotoxicity reaction. Infect Immun (1982) 0.94
Maturity as a critical determinant of resistance to fungal infections: studies in murine blastomycosis. Infect Immun (1982) 0.94
Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) (2014) 0.94
Chemical carcinogens transform BHK cells by inducing a recessive mutation. Mol Cell Biol (1982) 0.94
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Front Immunol (2015) 0.94
Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol (2015) 0.93
Transcriptional and epigenetic networks of helper T and innate lymphoid cells. Immunol Rev (2014) 0.93
Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy. Cell Mol Immunol (2012) 0.93
Natural killer cells: from basic research to treatments. Front Immunol (2011) 0.93
IL-15-PI3K-AKT-mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells. Front Immunol (2015) 0.93
Age-associated impairment of murine natural killer activity. Proc Natl Acad Sci U S A (1983) 0.92
Know Thyself: NK-Cell Inhibitory Receptors Prompt Self-Tolerance, Education, and Viral Control. Front Immunol (2014) 0.91
Natural killer cell activity in chickens: target cell analysis and effect of antithymocyte serum on effector cells. Infect Immun (1981) 0.91
A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities. Immunology (2011) 0.91
Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res (2010) 0.90
Genetic control of natural killing and in vivo tumor elimination by the Chok locus. J Exp Med (1998) 0.90
Further studies on the mitogenic and immune-modulating effects of plasminogen activator. Immunology (1982) 0.89
Human Circulating and Tissue-Resident CD56(bright) Natural Killer Cell Populations. Front Immunol (2016) 0.89
Potentiation of natural killer activity of human lymphocytes by Staphylococcus aureus bacteria and its protein A. Immunology (1981) 0.88
Liver natural killer cells: subsets and roles in liver immunity. Cell Mol Immunol (2015) 0.88
Suppressor cells induced by influenza virus inhibit interleukin-2 production in mice. Immunology (1990) 0.88
Natural killer cell regulation - beyond the receptors. F1000Prime Rep (2014) 0.88
Organ distribution of natural cytotoxicity in the rat. Clin Exp Immunol (1978) 0.88
Evidence for natural killer cell memory. Curr Biol (2013) 0.88
Interleukin-2-induced activation of natural killer activity in spleen cells from old and young mice. Immunology (1984) 0.88
Biological role of NK cells and immunotherapeutic approaches in breast cancer. Front Immunol (2012) 0.87
Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment. Proc Natl Acad Sci U S A (1982) 0.87
Beyond NK cells: the expanding universe of innate lymphoid cells. Front Immunol (2014) 0.87
Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvants of the beta(1 leads to 3) glucan-type lentinan and its analogues. Immunology (1980) 0.86
Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells. Nat Commun (2015) 0.85
Naturally occurring lymphocyte-mediated immunity to endogenous type-C virus in the mouse. Blocking of the lymphocyte reactivity with antisera to the virus. J Exp Med (1979) 0.85
Two independent receptors allow selective target lysis by T cell clones. J Exp Med (1983) 0.85
Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications. Front Immunol (2015) 0.84
In vivo modulation of thymus-derived lymphocytes with monoclonal antibodies in mice. III. Spontaneous and natural cytotoxic effector cells. Immunology (1984) 0.84
Modulation of human natural killer cytotoxicity by influenza virus and its subunit protein. Immunology (1984) 0.84
Membrane 126-kilodalton phosphoglycoprotein associated with human carcinomas identified by a hybridoma antibody to mammary carcinoma cells. Proc Natl Acad Sci U S A (1983) 0.84
Natural killer cell function of human neonatal lymphocytes. Clin Exp Immunol (1982) 0.84
Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med (1981) 5.76
Natural cell-mediated immunity. Adv Cancer Res (1978) 5.53
Natural killer cells: their roles in defenses against disease. Science (1981) 4.59
Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer (1975) 3.54
Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol (1977) 3.52
Natural killer cells: characteristics and regulation of activity. Immunol Rev (1979) 3.14
Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol (1984) 3.07
Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol (1981) 3.05
Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol (1979) 2.80
A functional comparison of human Fc-receptor-bearing lymphocytes active in natural cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol (1977) 2.60
Heterogeneity of natural killer cells. Annu Rev Immunol (1984) 2.59
Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med (1974) 2.40
Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic target cells. Int J Cancer (1977) 2.39
Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med (1989) 2.33
Natural killer (NK) cell activity in the rat. I. Isolation and characterization of the effector cells. J Immunol (1981) 2.12
Effectiveness of bicycle safety helmets in preventing serious facial injury. JAMA (1996) 2.05
Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol (1986) 2.05
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04
Low density of Thy 1 antigen on mouse effector cells mediating natural cytotoxicity against tumor cells. J Immunol (1978) 2.04
Immunosuppressive activity of a subline of the mouse EL-4 lymphoma. Evidence for minute virus of mice causing the inhibition. J Exp Med (1976) 2.01
Depletion of monocytes from human peripheral blood mononuclear leukocytes: comparison of the sephadex G-10 column method with other commonly used techniques. J Immunol Methods (1980) 1.92
Cytotoxic reactivity of human lymphocytes cultured in vitro. J Immunol (1977) 1.88
Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res (1989) 1.84
Cytolytic and cytostatic activity on tumor cells of circulating human monocytes. Int J Cancer (1979) 1.84
T-cell homeostasis in HIV infection is neither failing nor blind: modified cell counts reflect an adaptive response of the host. Nat Med (1997) 1.82
Positive self regulation of cytotoxicity in human natural killer cells by production of interferon upon exposure to influenza and herpes viruses. J Exp Med (1982) 1.81
Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol (1983) 1.79
Chédiak-Higashi gene in humans I. Impairment of natural-killer function. J Exp Med (1980) 1.79
Mechanism of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol (1986) 1.72
Breast conservation versus mastectomy: distress sequelae as a function of choice. J Clin Oncol (1989) 1.70
Inhibition of murine natural killer cell activity by prostaglandins. J Immunol (1980) 1.68
Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J Immunol (1975) 1.62
Cell-mediated immunity to tumor cells. Adv Cancer Res (1974) 1.60
Mastectomy versus breast conservation surgery: mental health effects at long-term follow-up. Health Psychol (1992) 1.56
Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol (1985) 1.55
Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int J Cancer (1972) 1.55
Fc receptors on mouse effector cells mediating natural cytotoxicity against tumor cells. J Immunol (1977) 1.53
Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J Immunol (1976) 1.53
Natural killer (NK) cells and their possible roles in resistance against disease. Clin Immunol Rev (1981) 1.52
Cell-mediated cytotoxicity for bladder carcinoma: evaluation of a workshop. Cancer Res (1975) 1.51
Natural killer activity in the rat. II. Analysis of surface antigens on LGL by flow cytometry. J Immunol (1981) 1.51
Gingivitis susceptibility and its relation to periodontitis in men. J Dent Res (2006) 1.50
Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer (1982) 1.50
Role of macrophages in the augementation of mouse natural killer cell activity by poly I:C and interferon. J Immunol (1979) 1.49
Identification and separation of Thy-1 positive mouse spleen cells active in natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Immunol (1979) 1.48
Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol (1999) 1.48
Prognosis versus actual outcome. III. The effectiveness of clinical parameters in accurately predicting tooth survival. J Periodontol (1996) 1.46
Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res (1990) 1.45
Low affinity E-rosette formation by the human K cell. J Immunol (1978) 1.45
Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels. Cancer Immunol Immunother (1992) 1.45
Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer (1992) 1.45
Effect of antibody to theta antigen on cell-mediated immunity induced in syngeneic mice by murine sarcoma virus. J Natl Cancer Inst (1973) 1.45
Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods (1992) 1.44
Natural cytotoxicity of mouse monocytes and macrophages. J Immunol (1979) 1.43
Natural cell-mediated cytotoxicity in mice against non-lymphoid tumor cells and some normal cells. Int J Cancer (1977) 1.42
Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer (1984) 1.42
Gene amplification and gene dosage in cell lines derived from squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer (1991) 1.42
Increased preventive practices lead to greater tooth retention. J Dent Res (2003) 1.42
Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver. J Exp Med (1984) 1.41
Effect of ultraviolet irradiation on MCA102 tumor cell immunogenicity and sensitivity to tumor necrosis factor. Cancer Res (1991) 1.41
Chédiak-Higashi gene in humans. II. The selectivity of the defect in natural-killer and antibody-dependent cell-mediated cytotoxicity function. J Exp Med (1980) 1.41
Mediation of mouse natural cytotoxic activity by tumour necrosis factor. Nature (1986) 1.39
Human T lymphocyte subpopulations: correlation between E-rosette-forming affinity and expression of the Fc receptor. J Immunol (1977) 1.39
Isolation of human and rat natural killer cells. J Immunol Methods (1982) 1.39
Phospholipid methylation and phospholipase A2 activation in cytotoxicity by human natural killer cells. Proc Natl Acad Sci U S A (1981) 1.39
Specificity of 51Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus. J Natl Cancer Inst (1974) 1.38
Natural cell-mediated cytotoxicity in rats. II. In vivo augmentation of NK-cell activity. Int J Cancer (1978) 1.38
Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells. J Immunol (1986) 1.37
Natural cell-mediated cytotoxicity in rats. III. Effects of immunopharmacologic treatments on natural reactivity and on reactivity augmented by polyinosinic-polycytidylic acid. Int J Cancer (1978) 1.37
Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukemia cell line. J Natl Cancer Inst (1977) 1.36
Destruction of human lymphoid tissue-culture cell lines by human peripheral lymphocytes in 51Cr-release cellular cytotoxicity assays. J Natl Cancer Inst (1974) 1.36
Microbial risk markers for childhood caries in pediatricians' offices. J Dent Res (2010) 1.35
Analysis by a single cell cytotoxicity assay of natural killer (NK) cells frequencies among human large granular lymphocytes and of the effects of interferon on their activity. J Immunol (1982) 1.34
Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal (1990) 1.32
Cytotoxicity by cultured human lymphocytes: characteristics of effector cells and specificity of cytotoxicity. J Immunol (1979) 1.32
The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol (1995) 1.32
Prognosis versus actual outcome. II. The effectiveness of clinical parameters in developing an accurate prognosis. J Periodontol (1996) 1.31
Wild-type gross leukemia virus: classification of soluble antigens (GSA). J Virol (1972) 1.31
An isotopic antiglobulin technique for measuring antibodies to cell-surface antigens. J Immunol (1969) 1.31
Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumour cells. Clin Exp Immunol (1971) 1.31
Natural cytotoxicity of mouse, rat, and human lymphocytes against heterologous target cells. J Natl Cancer Inst (1979) 1.30
Serological analysis of cell surface antigens of tumors induced by murine leukemia virus. J Natl Cancer Inst (1972) 1.29
Selective depletion of human natural killer cells on monolayers of target cells. J Immunol (1980) 1.29
Cutaneous hypersensitivity reactions to autologous extracts of malignant melanoma cells. Lancet (1970) 1.27
Rapid in vivo assay of mouse natural killer cell activity. J Natl Cancer Inst (1979) 1.26
In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J Immunol (1983) 1.26
Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J Immunol (1983) 1.25
Delayed cutaneous hypersensitivity reactions to autologous extracts of Burkitt-lymphoma cells. N Engl J Med (1970) 1.25
Immune reactivity of leukemia patients to autologous blast cells. Cancer Res (1972) 1.24